Thus, although HCC patients respond to anti-PD-1 therapy regardless of their baseline PD-L1 status (El-Khoueiry et al., 2017; Zhu et al., 2018; Sangro et al., 2020a, 2020b), these data support the inclusion of PD-L1 expression levels on tumor and immune cells in HCC tissues as part of a composite biomarker for atezolizumab plus bevacizumab first-line therapy. This evidence concerns the gene CD274 and hepatocellular carcinoma.